REAL-WORLD CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH METASTATIC DUCTAL ADENOCARCINOMA (MPDAC) TREATED WITH LIPOSOMAL IRINOTECAN-BASED REGIMENS BY RACE

被引：0
|
作者：
Kim, G. P. [1 ]
Cockrum, P. [2 ]
Lamarre, N. [3 ]
Surinach, A. [3 ]
机构：
[1] George Washington Univ, Washington, DC USA
[2] Ipsen, Cambridge, MA USA
[3] Genesis Res, Hoboken, NJ USA
来源：
VALUE IN HEALTH | 2021年 / 24卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN27
引用
收藏
页码：S23 / S23
页数：1
相关论文
共 50 条
  • [31] Real world outcomes of metastatic pancreatic cancer (mPC) patients (pts) treated with liposomal irinotecan (nalIRI) in the US.
    Barzi, Afsaneh
    Miksad, Rebecca
    Surinach, Andy
    Corvino, Frank A.
    Wang, Siqi
    Torres, Aracelis Z.
    Mamlouk, Khalid Kevin
    Pulgar, Sonia J.
    Bekaii-Saab, Tanios S.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [32] REAL-WORLD "CHAIR-TIME" BURDEN ASSOCIATED WITH INTRAVENOUS TREATMENT REGIMENS FOR PATIENTS WITH METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
    MacEwan, J.
    Surinach, A.
    Lamarre, N.
    Cockrum, P.
    VALUE IN HEALTH, 2022, 25 (07) : S326 - S326
  • [33] Real-world serum CA19-9 level monitoring patterns and its association with clinical outcomes among patients with metastatic pancreatic ductal adenocarcinoma (mPDAC).
    George, Ben
    Kent, Matthew
    Surinach, Andy
    Lamarre, Neil
    Cockrum, Paul
    Chudnovsky, Aleksander
    CANCER RESEARCH, 2021, 81 (13)
  • [34] Prior irinotecan exposure does not preclude benefit to liposomal irinotecan in patients with metastatic pancreatic ductal adenocarcinoma
    Yu, Kenneth H.
    Cockrum, Paul
    Surinach, Andy
    Lamarre, Neil
    Wang, Shu
    O'Reilly, Eileen M.
    CANCER MEDICINE, 2023, 12 (08): : 9496 - 9505
  • [35] A Retrospective Analysis of the Effect of Irinotecan-Based Regimens in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes
    Suo, Jiaojiao
    Zhong, Xiaorong
    He, Ping
    Zheng, Hong
    Tian, Tinglun
    Yan, Xi
    Luo, Ting
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [36] Clinical outcomes of liposomal irinotecan in patients with advanced pancreatic cancer previously treated with conventional irinotecan: A meta-analysis of real-world evidence
    Gupta, Amol
    De Jesus-Acosta, Ana
    Le, Dung
    Pishvaian, Michael
    Zaidi, Neeha
    Zheng, Lei
    Laheru, Daniel
    CANCER, 2024, 130 (21) : 3734 - 3744
  • [37] Real-world Impact of Age at Diagnosis on Treatment Patterns and Survival Outcomes of Patients with Metastatic Pancreatic Ductal Adenocarcinoma
    Elias, Rawad
    Cockrum, Paul
    Surinach, Andy
    Wang, Shu
    Chu, Bong Chul
    Shahrokni, Armin
    ONCOLOGIST, 2022, 27 (06): : 469 - 475
  • [38] Real-world safety data and differentiation of second-line (2L) 5-fluorouracil (5-FU) based regimens among patients with metastatic pancreatic ductal adenocarcinoma (mPDAC).
    Kim, George P.
    Cockrum, Paul
    Chudnovsky, Aleksander
    Surinach, Andy
    Wainberg, Zev A.
    Wang Shu
    Yakubu, Amin
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [39] Bevacizumab Plus Irinotecan-Based Therapy in Metastatic Colorectal Cancer Patients Previously Treated With Oxaliplatin-Based Regimens
    Yildiz, Ramazan
    Buyukberber, Suleyman
    Uner, Aytug
    Yamac, Deniz
    Coskun, Ugur
    Kaya, Ali Osman
    Ozturk, Banu
    Yaman, Emel
    Benekli, Mustafa
    CANCER INVESTIGATION, 2010, 28 (01) : 33 - 37
  • [40] The value of genetic polymorphisms to predict toxicity in metastatic colorectal patients with irinotecan-based regimens
    Lamas, M. J.
    Duran, G.
    Balboa, E.
    Bernardez, B.
    Candamio, S.
    Vidal, Y.
    Mosquera, A.
    Giraldez, J. M.
    Lopez, R.
    Carracedo, A.
    Barros, F.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (06) : 1591 - 1599
12345